SLC13A2 (NaDC1) is a low-affinity sodium-dicarboxylate cotransporter that mediates cellular uptake of tricarboxylic acid (TCA) cycle intermediates, including succinate, citrate, fumarate, and alpha-ketoglutarate, primarily in the small intestine and renal proximal tubule 123. The transporter operates via a 3 Na⁺:1 divalent anion stoichiometry, creating an electrogenic process, with citrate transported in its protonated divalent form 14. Mechanistically, SLC13A2 promotes hepatocyte citrate import, which serves as a precursor for ACLY-dependent acetyl-CoA formation and de novo cholesterol biosynthesis 5. In the kidney, apical SLC13A2 expression throughout the proximal tubule is critical for dicarboxylate reabsorption, acid-base homeostasis, and calcium nephrolithiasis prevention 6. SLC13A2 deficiency impairs intestinal succinate uptake, attenuating glucose tolerance improvements from dietary β-glucan 7. Clinically, SLC13A2 dysfunction associates with hypocitraturia and recurrent calcium oxalate kidney stone formation, with epistatic interaction involving VDR polymorphisms 8. SLC13A2 represents a potential therapeutic target for metabolic disorders including obesity, diabetes, and fatty liver disease 9. In gastric cancer, elevated SLC13A2 expression correlates with improved prognosis 10.